Scynexis Obtains Milestone Payment In Collaboration With Merck

Scynexis has received a payment from Merck, for achieving a preclinical milestone resulting from a collaboration to discover and develop novel oncology agents.

Yves Ribeill, president and CEO of Scynexis, said: “We are pleased to celebrate success in reaching another milestone with our valued partner, Merck. This milestone provides further validation of our long-term relationship with Merck in a number of therapeutic areas through discovery research and innovation.”

Scynexis is a premier drug discovery and development company headquartered in Research Triangle Park, North Carolina.

Scynexis research teams integrate medicinal chemistry, advanced biological screening, computational chemistry, bioanalysis and analytical chemistry and use powerful, proprietary technologies such as the HEOS Software Suite and MEDCHEM-FACTORY to advance molecules to candidate selection.